Company Overview and News
Paris (France) and Irving, TX (US), July 30, 2018 - Atos, a global leader in digital transformation, and CNA Financial Corporation, the eighth largest commercial insurer in the United States, today announced a new multi-year relationship where Atos will manage CNA's Information Technology (IT) infrastructure working with the insurer to transform its IT operations through orchestrated cloud migration and the rapid development of new services.
The market interpreted the updated EBITDA guidance as a 'miss', but failed to recognize the lower guidance was caused by external factors (US Sanctions against Iran).
SYNT INGIF EWQ ATONV
European stocks ended lower and marked a third straight loss on Monday, as shares of Fiat Chrysler Automobiles after the sudden departure of longtime chief Sergio Marchionne, amid a fresh round of earnings reports.
ATOS SE agreed to buy Syntel, Inc. in a $3.4-billion cash deal to boost the French computer-services provider’s US access, to customers including financials like American Express Co. and State Street Corp.
BNPZY STT BNPQY FDX BNPQF GTO ATONV
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SYNT BNPZY STT BNPQY FDX BNPQF GTO ATONV
July 22 (Reuters) - French technology services company Atos SE agreed to acquire Michigan-based Syntel Inc in an all-cash transaction valued at about $3.57 billion, including net debt, the companies said on Sunday.
French IT services company Atos SE agreed to acquire Syntel Inc in an all-cash transaction for about US$3.57 billion, including net debt, the companies said on Sunday.
2018-08-13 - Asif
Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...
2018-08-13 - Asif
Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...
2018-08-13 - Asif
Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...